Facilitation of Temozolomide Resistance of Glioblastoma by Long Noncoding RNA DLK1-35


Delta-like non-canonical Notch ligand 1-35, Glioma, Temozolomide


How to Cite

Li, Y. ., Zheng, X. ., Li, D. ., Sun, M. ., Wang, Z. ., Li, J. ., & Li, Y. (2023). Facilitation of Temozolomide Resistance of Glioblastoma by Long Noncoding RNA DLK1-35. Iranian Red Crescent Medical Journal, 25(5). https://doi.org/10.32592/ircmj.2023.25.5.2468


Background: Long noncoding RNAs played critical roles in glioblastoma development.

Objectives: This study aimed to examine the impacts of lncRNA DLK1-35 on glioblastoma cells and mice.

Methods: Methyl Thiazolyl Tetrazolium (MTT) was applied for examining the viabilities of U87 and U251 cells, as well as IC50 values of temozolomide (TMZ). LncRNA DLK1-35 expressions were detected using RT-qPCR. Proliferation and apoptosis of TMZ-resistant U251 (U251 TR) cells were evaluated using colony formation and flow cytometry, respectively. Western blot was applied to analyze O6-methylguanine-DNA methyltransferase (MGMT) protein expressions. The xenograft model was used for detecting the weight and volume of tumors in mice.

Results: TMZ treatment suppressed the viabilities of glioblastoma cells dose-dependently. Moreover, TMZ-resistant glioblastoma cells had higher IC50 values. lncRNA DLK1-35 was upregulated in TMZ-resistant cells while the suppression of lncRNA DLK1-35 caused low proliferation and a higher apoptosis rate. Moreover, MGMT was also inhibited by lncRNA DLK1-35 downregulation. Additionally, the weight and volume of tumors in mice were also inhibited with the knockdown of lncRNA DLK1-35.

Conclusion: Knockdown of lncRNA DLK1-35 inhibited MGMT to decrease the TMZ resistance in vitro and in vivo in glioblastoma.



Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X.

Advances in immunotherapy for glioblastoma multiforme. J Immunol Res. 2017;2017:3597613. doi: 10.1155/2017/3597613. [PubMed: 28299344]

Wirsching HG, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. [PubMed: 26948367]

Arora A, Somasundaram K. Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther. 2019;20(8):1083-90. doi: 10.1080/15384047.2019.1599662. [PubMed: 31068075]

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the Temozolomide resistance for Glioblastoma. Neurol Med Chir. 2018,58(10):405-21. doi: 10.2176/nmc.ra.2018-0141. [PubMed: 30249919]

Kim MM, Umemura Y, Leung D. Bevacizumab and Glioblastoma: past, present, and future directions. Cancer J. 2018;24(4):180-6. doi: 10.1097/PPO.0000000000000326. [PubMed: 30119081]

Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846-52. [PubMed: 3664486]

Davis ME. Epidemiology and overview of Gliomas. Semin Oncol Nurs. 2018;34(5):420-9. doi: 10.1016/j.soncn.2018.10.001. [PubMed: 30392758]

Xia Q, Liu L, Li Y, Zhang P, Han D, Dong L. Therapeutic perspective of temozolomide resistance in Glioblastoma treatment. Cancer Invest. 2021;39(8):627-44. doi: 10.2176/nmc.ra.2018-0141. [PubMed: 30249919]

Peng Y, Tang D, Zhao M, Kajiyama H, Kikkawa F, Kondo Y. Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer. Cancer Metastasis Rev. 2020;39(3):825-35. doi: 10.1007/s10555-020-09910-w. [PubMed: 32594276]

Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093-100. doi: 10.1111/cas.13642. [PubMed: 29774630]

Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19(1):28. doi: 10.1186/s12943-020-1137-5. [PubMed: 32039732]

Qi J, Pan L, Yu Z, Ni W. The lncRNA RP3-439F8.1 promotes GBM cell proliferation and progression by sponging miR-139-5p to upregulate NR5A2. Pathol Res Pract. 2021;223:153319. doi: 10.1016/j.prp.2020.153319. [PMID: 33991848]

Zeng H, Xu N, Liu Y, Liu B, Yang Z, Fu Z, et al. Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. Int J Oncol. 2017;51(2):445-55. doi: 10.3892/ijo.2017.4033. [PubMed: 28714520]

DeSouza PA, Qu X, Chen H, Patel B, Maher CA, Kim AH.

Long, noncoding RNA dysregulation in Glioblastoma. Cancers. 2021;13(7):1604. doi: 10.3390/cancers13071604. [PubMed:33807183]

Shangguan W, Lv X, Tian N. FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in

a O(6)-methylguanine-DNA methyltransferase-dependent manner. Korean J Physiol Pharmacol. 2019;23(6):475-82. doi: 10.4196/kjpp.2019.23.6.475. [PubMed: 31680769]

Wu P, Cai J, Chen Q, Han B, Meng X, Li Y, et al. Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019;10(1):2045. doi: 10.1038/s41467-019-10025-2. [PubMed: 31053733]

Cai T, Liu Y, Xiao J. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer Med. 2018;7(4):1404-15. doi: 10.1002/cam4.1384. [PubMed: 29479863]

Lou J, Yan W, Li QY, Zhu AK, Tan BQ, Dong R, Zou XZ, Liu T. LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis. Neoplasma. 2021;68(2):273-82.

Rao AM, Quddusi A, Shamim MS, The significance of MGMT methylation in Glioblastoma Multiforme prognosis. J Pak Med Assoc. 2018;68(7):1137-9. [PubMed: 30317322]

Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. [PubMed: 30258889]